| To view video and slides of these presentations, click on presentation title. This will open a new browser window in which the audio, video, and slides for that presentation will be shown. If you have problems viewing the presentations via the Internet, we are offering a DVD version of the conference presentations for viewing on computers running Windows XP. At this time the DVD is free. To order, please e-mail eppinger@cmu.edu. |
| Monday, October 24, 2005 |
| Plenary Session |
| Welcome and Introduction Francesmary Modugno, PhD, MPH • University of Pittsburgh Ronald B. Herberman, MD • University of Pittsburgh |
| Opening Keynote: Genetic Analysis of Ovarian Cancer Histogenesis Jeff Boyd, PhD, MPH • Memorial Sloan-Kettering Cancer Center |
| Epidemiology of Ovarian Cancer |
| Molecular Studies of Ovarian Cancer in a Multiethnic Population Marc T. Goodman, PhD, MPH • University of Hawaii |
| Screening for Ovarian Cancer in High Risk Women Patricia Hartge, ScD • National Cancer Institute |
| New Directions in Ovarian Cancer Epidemiology and Prevention Joellen Schildkraut, PhD • Duke University |
| Panel Discussion Roberta B. Ness, MD, MPH • University of Pittsburgh |
| From Epidemiology to Ovarian Cancer Biology |
| Pregnancy and Ovarian Cancer: Role of Endogenous Hormones Paolo Toniolo, MD, MSPH • New York University |
| Modeling Epithelial Ovarian Cancer in the Mouse Denise Connolly, PhD • Fox Chase Cancer Center |
| Mechanism of Ovarian Cancer Predisposition in Individuals with Germline BRCA1 Mutation Louis Dubeau, MD, PhD • University of Southern California |
| Panel Discussion Emanuela Taioli, MD, PhD • University of Pittsburgh |
| Screening and Early Detection – Emerging Technologies |
| A Proteomics Approach to the Detection of Ovarian Cancer Eric Fung, MD, PhD • Ciphergen Diagnostics (Video and slides cannot be made available for this presentation) |
| Application of Proteomics Technologies to Advance our Understanding of Ovarian Cancer Elise Kohn, MD • National Cancer Institute (Video and slides cannot be made available for this presentation) |
| Can We Detect Early Stage Epithelial Ovarian Carcinoma? David Fishman, MD • New York University |
| Multiplexed Serum Assay for Early Detection of Ovarian Cancer Anna Lokshin, PhD • University of Pittsburgh |
| Panel Discussion Joel Weissfeld, MD, MPH • University of Pittsburgh |
| Genetic and Epigenetics |
| An Update on the HapMap Wendy Wang, PhD • National Cancer Institute (Video and slides cannot be made available for this presentation) |
| Prevention and Early Detection in Women at Increased Genetic Risk Mark H. Greene, MD • National Cancer Institute |
| Variable Expression and Activity of Pharmacokinetic Variables in Ovarian Tumors Julie A. DeLoia, PhD • University of Pittsburgh |
| Panel Discussion Francesmary Modugno, PhD, MPH • University of Pittsburgh |
| Survivor and Advocate Educational Session |
| Survivor and Advocacy Groups: A Role in Research, Education, and Beyond Julene Fabrizio, President • National Ovarian Cancer Coalition Patricia Goldman, President Emeritus • Ovarian Cancer National Alliance |
| Complementary and Alternative Therapies for Ovarian Cancer Patients: Overview Maria B. Yaramus, PharmD • University of Pittsburgh |
| Magee-Womens Hospital Holistic Center Ovarian Cancer Support Group Karen Cooper, LCSW • Magee-Womens Hospital of UPMC |
| T’ai Chi, Chi Kung, and Supportive Care David Clippinger, PhD • Still Mountain T’ai Chi and Chi Kung |
| Restorative Yoga and Supportive Care Leta Koontz • Schoolhouse Yoga |
| Meditation and Guided Imagery: Pathways to Spiritual Health and Well-Being Brenda Cole, PhD • University of Pittsburgh |
| Healthy Choices and Healthy Snacking Rita Beaver, RD • Magee-Womens Hospital of UPMC Chris Fennimore • WQED Multimedia |
| Acupuncture and Symptom Distress Ronald Glick, MD • University of Pittsburgh |
| Methods of Diagnosis using Acupuncture Jim Poepperling L.Ac. SDPT, MTOM • University of Pittsburgh Medical Center |
| Reception and Mini-Symposium |
| Abstracts |
| Tissue Microarray Analysis of Biomarkers p53, BRCA1, Annexin I, and Gelsolin Supports the Two-Pathway Theory of Ovarian Serous Carcinoma Peggy Soung, MD • University of California at Los Angeles |
| United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Design and Characteristics of the Study Population Usha Menon, MD, MRCOG, MBBS • University College London |
| 1H-NMR-Based Metabonomics for the Detection of Epithelial Ovarian Cancer Kunle Odunsi, MD, PhD • Roswell Park Cancer Institute |
| Identifying Associations between SNPs in Cell Cycle Control Genes and Susceptibility to Ovarian Cancer Simon Gayther • University College London |
| Gene expression profiling of ovarian tumors obtained prior to and after chemotherapy: identification of putative marks implicated in mechanisms of chemoresistance Sylvain L’Esperance • Centre de recherche de l’H�tel-Dieu de Qu�bec (Video and slides cannot be made available for this presentation) |
| A Role for Micro Tubule-Associated Serine Protease HtrA1 in Chemotherapy-induced Cytotoxcity Jeremy Chein, PhD • Mayo Clinic College of Medicine |
| Tuesday, October 25, 2005 |
| Plenary Session |
| Plenary Keynote: The Challenges of Reducing Overian Cancer Mortality Karen Johnson, MD, PhD, MPH • Branch Chief, Breast and Gynecologic Malignancies, National Cancer Institute |
| Beyond Treating the Patient – Survivorship Issues |
| Advocacy, Patient Care, and the Research Community Julene Fabrizio, President • Ovarian Cancer National Alliance |
| Beyond Treating the Patient Patricia Goldman, President Emeritus • Ovarian Cancer National Alliance |
| Ovarian Cancer: Insider Perspectives Barbara Smith • National Ovarian Cancer Coalition Cynthia DePastino • National Ovarian Cancer Coalition |
| Psycho-Social Issues in Diagnosis and Recurrence: Effects on Patients and their Families Heidi Donovan, PhD • University of Pittsburgh |
| Integrating Complementary Medicine with Conventional Treatment Ronald Glick, MD • University of Pittsburgh Medical Center |
| New Directions in Therapeutics and Prevention I |
| Peritoneal Immunotherapy Ralph S. Freedman, MD, PhD • University of Texas |
| Vaccines Targeting Ovarian Cancer Mary L. (Nora) Disis, MD • University of Washington |
| Immunobiology of MUC1 Tumor Antigen: Lessons Learned and Future Implications in Ovarian Cancer Anda Vlad, MD, PhD • University of Pittsburgh |
| Evolution of NY-ESO-1 Vaccine Therapy for Ovarian Cancer Kunle Odunsi, MD, PhD • Roswell Park Cancer Institute |
| Panel Discussion Kristin Zorn, MD • Magee-Womens Hospital of UPMC |
| New Directions in Therapeutics and Prevention II |
| TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemo-Resistance in Ovarian Cancer Thomas Rutherford, MD, PhD • Yale University |
| Oregovomab: Challenges, Lessons, and Opportunities Christopher Nicodemus, MD • Unither Pharmaceuticals, Inc |
| Novel Approaches for Platinum Refractive Cancer Robert P. Edwards, MD • Magee-Womens Hospital of UPMC |
| Individualizing Cancer Therapy: Current Status, Future Directions Holly Gallion, MD • Precision Therapeutics, In |
| Panel Discussion Thomas Krivak, MD • Magee-Womens Hospital of UPMC |
An NCI-designated Comprehensive Cancer Center, affiliated with the University of Pittsburgh School of Medicine
Research
